Norketotifen is under clinical development by Emergo Therapeutics and currently in Phase I for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis). According to GlobalData, Phase I drugs for Chronic ...
This is the first study to summarise illness characteristics of a cohort of Polish chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) patients. We used Fukuda criteria to indicate patients ...
In 2021, the National Institute for Health and Care Excellence produced an evidence-based guideline on the diagnosis and management of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
post-treatment Lyme disease (PTLD), and Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The study will enroll up to 160 participants, with first patient dosed anticipated in early Q1 ...
ME/CFS actually first started out as just “ME,” or myalgic encephalomyelitis ... which can keep you from helpful treatment or advice on how to manage your symptoms, Dr. Shepherd says.